Evaluating the De-Escalation of Surveillance for Patients Who Have Undergone Curative Treatment for Primary Breast Cancer (De-Escalation)
Breast cancer is the most common cancer in women around the world. That means a lot of women are affected by it every year, and it's important that we always look for ways to improve their care, not just during treatment, but afterwards too. After treatment for early-stage breast cancer, patients usually come back to the hospital for regular check-ups for up to five years. These visits are based on old guidelines, and even though breast cancer treatment has improved a lot over the years, the follow-up schedule has stayed the same. This study is being done to see if we can safely reduce the number of hospital visits after treatment, while still keeping patients healthy and well looked after.
Right now, patients are asked to attend follow-up appointments at 6, 12, 18, 24, 36, 48 and 60 months (that's every 6 to 12 months for five years). These clinic visits often involve long waits and can cause stress or anxiety. At the same time, patients are also invited for a mammogram once a year. Recent research shows that most recurrences of breast cancer are found by patients themselves or during their annual mammograms, not necessarily at these clinic visits. That's why we're looking at whether we can safely reduce the number of hospital appointments, without affecting patient safety.
In this study, some patients will continue with the usual five-year clinic schedule. Others will only attend hospital clinics for the first two years (at 6, 12, 18 and 24 months), and after that, they will no longer need to come in for the extra follow-up visits, but they will still have their annual mammograms as normal.
Within this study all participants will complete a short questionnaire once a year. This will help us understand how the different follow-up plans affect quality of life, and how patients feel about their care. This research study is taking place to find out if fewer hospital check-ups, combined with continued mammogram screening, is just as safe and possibly better for patients' wellbeing.
調査の概要
詳細な説明
This study began in 2025 at the Breast Centre in Beaumont RCSI Cancer Centre. We expect that around 600 people will take part. If you agree to join the study, you will be placed into one of two groups:
- One group will continue with the usual follow-up plan after breast cancer treatment. This includes regular hospital visits for up to five years.
- The other group will follow a new plan, where hospital visits will stop after two years, but yearly mammograms will continue as normal.
- Participants will continue to have access to the breast care team by the usual contact points such as your breast care nurse. All patients following treatment of breast cancer in Beaumont hospital are provided with a direct phone number to contact the breast care nurse should they have any concern.
Participants won't need to take any new medicines or treatments. Each year, we'll ask you to complete a short questionnaire (either in person or over the phone) to tell us how participants are feeling and how the follow-up process is working for them.
This will help the researchers understand whether the new follow-up plan is just as safe and possibly more convenient for patients.
Participants will be placed into one of two groups, this will be chosen at random (like flipping a coin). Both groups will be followed for a total of five years after their breast cancer treatment.
Group 1 - Current Follow-Up Plan (Usual Care):
- Continue with the current schedule of hospital clinic visits at: 6, 12, 18, 24, 36, 48 and 60 months after your treatment
- Be invited for your annual mammogram as normal
- Be asked to fill in a short questionnaire at your clinic visits at 24, 36, 48, and 60 months. This will help us understand how you're feeling and your experience with follow-up care
- All your appointments will take place in person at the Breast Centre in Beaumont Hospital.
Group 2 - New Follow-Up Plan (Study Group):
- Attend clinic visits at: 6, 12, 18, and 24 months after treatment
- Be discharged from hospital clinics after 2 years
- Continue to have your annual mammogram as normal
- Fill in the same questionnaire at 24 months in person, and then by telephone at 36, 48 and 60 months
- If you are in this group and ever feel you would prefer to return to hospital clinic visits, you will be supported to do so.
No extra hospital visits, medical tests, or blood samples are required for this study. The questionnaire may ask about your health, daily activities, and how you feel about the follow-up care you are receiving. Some people may find questions about quality of life or cancer follow-up a little emotional or upsetting, but you can skip any question you don't want to answer. Researchers may look at medical records to check information about diagnosis, treatment, and follow-up care. This will be done confidentially, and only by members of the research team who are trained to handle personal health information safely.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Aisling Hegarty, PhD
- 電話番号:018093000
- メール:Aislinghegarty@rcsi.ie
研究連絡先のバックアップ
- 名前:Prof Arnold Hill, MB, BCh, BAO, MCh, FRCSI
- 電話番号:+35318093000
- メール:adkhill@rcsi.com
研究場所
-
-
Dublin
-
Beaumont、Dublin、アイルランド、D09V2N0
- 募集
- Beaumont RCSI Cancer Centre
-
コンタクト:
- Aisling Hegarty, PhD
- 電話番号:018093000
- メール:Aislinghegarty@rcsi.ie
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Participants will be identified according to the eligibility criteria and will be approached and invited to participate in this study while attending the outpatient department at the breast centre in Beaumont Hospital. To be eligible to participate in this study, an individual must meet all of the following eligibility criteria:
- Female patients who are under cancer surveillance for a primary breast cancer which was treated with curative intent
- Aged 18 years or older at the time of 24-month surveillance
- Demonstrate no clinical or radiological evidence of disease recurrence or metastases at the time of recruitment (e.g.: palpable mass, skin or nipple changes, new indeterminant mass on mammography, etc)
- Fully fluent in English Language (Reading, Writing, and Speaking - has the ability to complete the EQ5D5L questionnaire in paper form and over the phone)
- Has a formal address in the Republic of Ireland and has the intention of undergoing further surveillance in this country
Exclusion Criteria:
All individuals meeting any of the exclusion criteria at baseline or during screening will be excluded from study participation as per the following criteria: - An individual who fails to meet any of the aforementioned inclusion criteria will be excluded from participation in this study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Intervention
Intervention group:
|
Reduction in hospital based appointments to 2 years only and discharge to primary care for follow up post same.
|
|
アクティブコンパレータ:Control
Control Group:
|
標準治療
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Health-Related Quality of Life Measured by the EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L)
時間枠:Measured at months 24, 36, 48 and 60 post randomisation.
|
Health-related quality of life measured using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L).
The EQ-5D-5L evaluates five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each scored on five response levels.
Responses will be converted to an EQ-5D-5L index score using validated scoring methods.
Higher index scores indicate better health-related quality of life.
|
Measured at months 24, 36, 48 and 60 post randomisation.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Breast Cancer Recurrence During Follow-Up
時間枠:Measured with annual mammogram and clinical outcomes at months 12, 24, 36, 48 and 60 post randomisation.
|
Number of participants with breast cancer recurrence identified during follow-up through annual mammography, clinical assessment, patient-reported symptoms, or medical record review.
|
Measured with annual mammogram and clinical outcomes at months 12, 24, 36, 48 and 60 post randomisation.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
乳がんの臨床試験
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated... と他の協力者完了
-
Novartis Pharmaceuticals終了しましたメラノーマ | 高度なEGFR変異体非小さな細胞肺cancer(NSCLC) | KRAS G12変異NSCLC | 食道扁平上皮がん(SCC) | ヘッド/ネックSCC | 進行した胃腸間質腫瘍(GIST) | 進行したNRAS/BRAFT WT皮膚黒色腫アメリカ, 台湾, オランダ, カナダ, スペイン, シンガポール, イタリア, 日本, 韓国
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight Therapeutics積極的、募集していない平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件アメリカ
コントロールの臨床試験
-
University of Southern MississippiMilitary Suicide Research Consortium招待による登録
-
Indiana UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)終了しました
-
University of British ColumbiaUniversity of Victoria; Social Sciences and Humanities Research Council of Canada完了
-
W.L.Gore & Associates完了胸部疾患スウェーデン, オランダ, スペイン, ドイツ, フランス, イギリス, イタリア
-
Rethink Medical SLEvidenze Health España (CRO); Centro para el Desarrollo Tecnológico y la Innovación (CDTI),...一時停止生活の質 | カテーテル;感染症(留置カテーテル) | カテーテル関連の合併症ポルトガル, スペイン
-
Devicare S.L.Clever Instruments S.L.; Fundacio Puigvertわからない
-
Linkoeping UniversityThe Swedish Research Council; the Swedish Research Council for Health, Working Life and Welfare募集